Dr. El-Khalili is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3660 Rome Dr
Lafayette, IN 47905Phone+1 765-446-9394Fax+1 765-447-8875
Education & Training
Indiana University School of Medicine (Indianapolis)Residency, Psychiatry, 1982 - 1986
Damascus University Faculty of MedicineClass of 1978
Certifications & Licensure
FL State Medical License 2022 - 2027
IL State Medical License 2023 - 2026
IN State Medical License 1984 - 2025- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy Start of enrollment: 2013 Nov 01
- Open-label Safety Study in Adults With ADHD Start of enrollment: 2014 Jun 01
Publications & Presentations
PubMed
- 3 citationsPooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.Michael Bauer, Koen Demyttenaere, Nizar El-Khalili, Michael E. Thase, George I. Papakostas
International Clinical Psychopharmacology. 2014-01-01 - 13 citationsUpdate on extended release quetiapine fumarate in schizophrenia and bipolar disorders.Nizar El-Khalili
Neuropsychiatric Disease and Treatment. 2012-11-08 - 63 citationsEfficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study.Brian Bortnick, Nizar El-Khalili, Michael Banov, David E. Adson, Catherine Datto
Journal of Affective Disorders. 2011-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
